Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Hamblin

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Molecular Pharmacology|January 1, 1982
Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranesM W Hamblin, I Creese
Life Sciences|May 3, 1982
3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodiumM W Hamblin, I Creese
Life Sciences|May 9, 1983
Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolineM W Hamblin, I Creese
Molecular Pharmacology|January 1, 1982
Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranesM W Hamblin, I Creese
Molecular Pharmacology|August 1, 1991
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptorM W Hamblin, M A Metcalf
Biochemical Pharmacology|March 15, 1984
Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranesM W Hamblin, S E Leff, I Creese
Molecular Pharmacology|February 1, 1985
Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding statesS E Leff, M W Hamblin, I Creese
Biochemical Pharmacology|November 17, 1992
Conversion of the human 5-HT1D beta serotonin receptor to the rat 5-HT1B ligand-binding phenotype by Thr355Asn site directed mutagenesisM A Metcalf, R W McGuffin, M W Hamblin
Brain Research. Developmental Brain Research|January 15, 1991
Developmental regulation of 5-HT2 and 5-HT1c mRNA and receptor levelsB L Roth, M W Hamblin, R D Ciaranello
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 1, 1996
Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleusJ F Neumaier, D C Root, M W Hamblin
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Molecular Pharmacology|January 1, 1982
Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranesM W Hamblin, I Creese
Life Sciences|May 3, 1982
3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodiumM W Hamblin, I Creese
Life Sciences|May 9, 1983
Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolineM W Hamblin, I Creese
Molecular Pharmacology|January 1, 1982
Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranesM W Hamblin, I Creese
Molecular Pharmacology|August 1, 1991
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptorM W Hamblin, M A Metcalf
Biochemical Pharmacology|March 15, 1984
Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranesM W Hamblin, S E Leff, I Creese
Molecular Pharmacology|February 1, 1985
Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding statesS E Leff, M W Hamblin, I Creese
Biochemical Pharmacology|November 17, 1992
Conversion of the human 5-HT1D beta serotonin receptor to the rat 5-HT1B ligand-binding phenotype by Thr355Asn site directed mutagenesisM A Metcalf, R W McGuffin, M W Hamblin
Brain Research. Developmental Brain Research|January 15, 1991
Developmental regulation of 5-HT2 and 5-HT1c mRNA and receptor levelsB L Roth, M W Hamblin, R D Ciaranello
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 1, 1996
Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleusJ F Neumaier, D C Root, M W Hamblin
Pageof 4